Mean Heart Dose-based Normal Tissue Complication Probability Model for Pericardial Effusion: a Study in Oesophageal Cancer Patients

Overview

Journal Sci Rep

Specialty Science

Date 2021 Sep 14

PMID 34518576

Citations 3

Authors

Junichi Fukada

Kyohei Fukata

Naoyoshi Koike

Ryuichi Kota

Naoyuki Shigematsu

Affiliations

Soon will be listed here.

Abstract

We investigated the normal tissue complication probability (NTCP) of the incidence of pericardial effusion (PCE) based on the mean heart dose (MHD) in patients with oesophageal cancer treated with definitive chemoradiotherapy. The incidences of PCE in any grade (A-PCE) and symptomatic PCE (S-PCE) were evaluated separately. To identify predictors for PCE, several clinical and dose-volume parameters were analysed using a receiver operating characteristic (ROC) curve and multivariate regression analysis. To validate its clinical applicability, the generated NTCP model was compared to the Lyman-Kutcher-Burman (LKB) model. Among 229 eligible patients, A-PCE and S-PCE were observed in 100 (43.7%) and 18 (7.9%) patients, respectively. MHD showed a preferable area under the curve (AUC) value for S-PCE (AUC = 0.821) and A-PCE (AUC = 0.734). MHD was the only significant predictor for A-PCE; MHD and hypertension were selected as significant factors for S-PCE. The estimated NTCP, using the MHD-based model, showed excellent correspondence to the LKB model in A-PCE and S-PCE. The NTCP curve of A-PCE was gentler than that of S-PCE and had no threshold. The MHD-based NTCP model was simple but comparable to the LKB model for both A-PCE and S-PCE. Therefore, the estimated NTCP may provide clinically useful parameters for predicting PCE.

Citing Articles

Moving beyond mean heart dose: The importance of cardiac substructures in radiation therapy toxicity.

Bowen Jones S, Marchant T, Saunderson C, McWilliam A, Banfill K J Med Imaging Radiat Oncol. 2024; 68(8):974-986.

PMID: 39228181 PMC: 11686456. DOI: 10.1111/1754-9485.13737.

Application research on reducing radiation-induced lung injury with a trigger operator based on overlap volume histogram (OVH) in breast cancer postoperative radiotherapy.

Li Q, Deng F, Pan X, Bai H, Bai J, Liu X Sci Rep. 2023; 13(1):22042.

PMID: 38086847 PMC: 10716111. DOI: 10.1038/s41598-023-49282-z.

Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer.

Oonsiri S, Kitpanit S, Kannarunimit D, Chakkabat C, Lertbutsayanukul C, Prayongrat A Phys Imaging Radiat Oncol. 2022; 22:51-56.

PMID: 35514527 PMC: 9065423. DOI: 10.1016/j.phro.2022.04.005.

References

Hancock S, Donaldson S, Hoppe R . Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993; 11(7):1208-15. DOI: 10.1200/JCO.1993.11.7.1208. View

Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H . Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2013; 87(3):487-93. DOI: 10.1016/j.ijrobp.2013.07.008. View

Niemierko A . Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997; 24(1):103-10. DOI: 10.1118/1.598063. View

Dawson L, Normolle D, Balter J, McGinn C, Lawrence T, Ten Haken R . Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002; 53(4):810-21. DOI: 10.1016/s0360-3016(02)02846-8. View

Burman C, Kutcher G, Emami B, Goitein M . Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991; 21(1):123-35. DOI: 10.1016/0360-3016(91)90172-z. View

Kwa S, Lebesque J, Theuws J, Marks L, Munley M, Bentel G . Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998; 42(1):1-9. DOI: 10.1016/s0360-3016(98)00196-5. View

Chahine J, Shekhar S, Mahalwar G, Imazio M, Collier P, Klein A . Pericardial Involvement in Cancer. Am J Cardiol. 2021; 145:151-159. DOI: 10.1016/j.amjcard.2020.12.092. View

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider J . Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1):109-22. DOI: 10.1016/0360-3016(91)90171-y. View

Contreras J, Lin A, Weiner A, Speirs C, Samson P, Mullen D . Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2018; 128(3):498-504. DOI: 10.1016/j.radonc.2018.05.017. View

10.

Wang K, Eblan M, Deal A, Lipner M, Zagar T, Wang Y . Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. J Clin Oncol. 2017; 35(13):1387-1394. PMC: 5455462. DOI: 10.1200/JCO.2016.70.0229. View

11.

Bradley J, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two.... Lancet Oncol. 2015; 16(2):187-99. PMC: 4419359. DOI: 10.1016/S1470-2045(14)71207-0. View

12.

Wei X, Liu H, Tucker S, Wang S, Mohan R, Cox J . Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008; 70(3):707-14. DOI: 10.1016/j.ijrobp.2007.10.056. View

13.

Fukada J, Shigematsu N, Ohashi T, Shiraishi Y, Takeuchi H, Kawaguchi O . Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer. J Radiat Res. 2012; 53(3):447-53. DOI: 10.1269/jrr.11194. View

14.

Pao T, Chang W, Chiang N, Lin C, Lai W, Tseng Y . Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer. Radiat Oncol. 2020; 15(1):48. PMC: 7045635. DOI: 10.1186/s13014-020-01498-3. View

15.

Moons K, Altman D, Reitsma J, Ioannidis J, Macaskill P, Steyerberg E . Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015; 162(1):W1-73. DOI: 10.7326/M14-0698. View

16.

Feng M, Moran J, Koelling T, Chughtai A, Chan J, Freedman L . Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2010; 79(1):10-8. PMC: 2937165. DOI: 10.1016/j.ijrobp.2009.10.058. View

17.

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N . Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2010; 81(3):684-90. DOI: 10.1016/j.ijrobp.2010.06.033. View

18.

Szpakowski N, Desai M . Radiation-Associated Pericardial Disease. Curr Cardiol Rep. 2019; 21(9):97. DOI: 10.1007/s11886-019-1192-y. View

19.

Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A . Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ. 2003; 326(7383):256-7. PMC: 140764. DOI: 10.1136/bmj.326.7383.256. View

20.

Semenenko V, Li X . Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol. 2008; 53(3):737-55. DOI: 10.1088/0031-9155/53/3/014. View